The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 26, 2005
Filed:
Apr. 14, 2003
Kazunari Yamashita, Kyoto, JP;
Eiji Hashimoto, Wakayama, JP;
Yukihiro Nomura, Osaka, JP;
Fumio Shimojo, Hyogo, JP;
Shigeki Tamura, Osaka, JP;
Takeo Hirose, Kyoto, JP;
Satoshi Ueda, Hyogo, JP;
Takashi Saitoh, Osaka, JP;
Rinta Ibuki, Kyoto, JP;
Toshio Ideno, Osaka, JP;
Kazunari Yamashita, Kyoto, JP;
Eiji Hashimoto, Wakayama, JP;
Yukihiro Nomura, Osaka, JP;
Fumio Shimojo, Hyogo, JP;
Shigeki Tamura, Osaka, JP;
Takeo Hirose, Kyoto, JP;
Satoshi Ueda, Hyogo, JP;
Takashi Saitoh, Osaka, JP;
Rinta Ibuki, Kyoto, JP;
Toshio Ideno, Osaka, JP;
Fujisawa Pharmaceutical Co., Ltd., Osaka, JP;
Abstract
Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanes Pharmacopocia, the 13-th edition, Dissolution Test, No. 2 (Puddles method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprises a solid base which is a water-soluble or water-insoluble polymer. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. The formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune disease. In addition, a solid dispersion composition is provided. The solid dispersion comprises tacrolimus or its hydrate in a mixture containing water-soluble or water-insoluble polymer and an excipient.